论文部分内容阅读
COX-2 has long been exploited in the treatment of inflammation and relief of pain; however,research increasingly suggests COX-2 inhibitors might possess potential benefits to thwart tumour processes.In the present study,we designed a series of novel COX-2 inhibitors based on analysis of known inhibitors combined with an in silico scaffold modification strategy.A docking simulation combined with a primary screen in vitro were performed to filter for the lead compound,which was then substituted,synthesized and evaluated by a variety of bioassays.Derivative 4d was identified as a potent COX-2 enzyme inhibitor and exerted an anticancer effect through COX-2 inhibition.Further investigation confirmed that 4d could induce A549 cell apoptosis and arrest the cell cycle at the G2/M phase.Moreover,treatment with 4d reduced A549 cell adhesive ability and COX-2 expression.The morphological variation of treated cells was also visualized by confocal microscopy.Overall,the biological profile of 4d suggests that this compound may be developed as a potential anticancer agent.